Grifols, S.A.

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced the acquisition of its first donation center in Canada as part of the company's commitment to increase the availability of lifesaving plasma medicines in the country. In a share-purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc's (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash.

Grifols acquires its first plasma donation center in Canada

BARCELONA, Spain, Nov. 30, 2021 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in the development of plasma-derived therapies, today announced the opening of its 300th plasma donor center in the U.S., the company's first-ever donation center in the state of Massachusetts and second in New England. Located in the VA Building at the UMass Chan Medical School campus in Worcester, Mass.

Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma

BARCELONA, Spain, Nov. 4, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest albumin portfolio innovation, ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations.

Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals

BARCELONA, Spain, Oct. 19, 2021 /PRNewswire/ -- Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record of contributing to the health and well-being of people around the world, and the National Service Projects Organization (NSPO) in Egypt today inaugurated the first integrated plasma-supply platform in Africa, the start of a robust plasma infrastructure that will bring self-sufficiency to Egypt while facilitating access to plasma products for the broader Middle East and African region, as well as other countries.     Innovative in its goals and scope, the alliance that Grifols and Egypt announced in November 2020 is the first ever that pairs a government entity and a private plasma manufacturer to tackle national self-sufficiency.

Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines

Spanish pharmaceutical company Grifols SA said Friday that it has reached an agreement to acquire a majority stake in German peer Biotest AG.

Pharma deal: Biotest up 12% after Grifols to pay $1.3 billion for majority stake

Spain-based biotech Grifols SA ( GRFS , Financial) is trading low due to the effects of the pandemic on sales and revenue. The company is completely vertically integrated in the plasma business.

Grifols Sells Off With Effects of Pandemic

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Grifols (GRFS)

Grifols outlines some promising new initiatives and financial targets at its latest Capital Markets Day. The most notable shift this time around was the R&D/innovation focus, which should boost the longer-term growth outlook.

Grifols: Valuation Discount Remains Wide Despite An Upbeat Capital Markets Day

Singapore's wealth fund GIC agreed to invest around 1 billion dollars in Biomat, a U.S.-based plasma collection company owned by Grifols, thus becoming a strategic investor in the Spanish pharmaceutical company, Grifols said on Wednesday.

Singapore's sovereign fund invests $1 billion in Grifols's U.S. unit

BARCELONA, Spain, June 1, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and IgG products for patients, today began commercializing HyperHEP B, a new formulation of its hepatitis B immune globulin [human] for hepatitis B postexposure prophylaxis. The new formulation, which was approved by the U.S. Food and Drug Administration (FDA) in December 2020, uses a unique caprylate chromatography process, which significantly reduces procoagulant activity and IgG aggregates.

Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B

The center will collect real-world data on AMBAR® clinical program - AMBAR® Center combines Grifols' more than 15 years of knowledge researching this devastating disease with the experience of the non-profit medical foundation Ace Alzheimer Center Barcelona in diagnosing and treating Alzheimer's patients, including application of AMBAR® (Alzheimer Management by Albumin Replacement) - The AMBAR® clinical program, based on periodic plasma exchange with albumin, has shown a delay in the cognitive and functional progression of Alzheimer's disease in mild-to-moderate patients - Ace Alzheimer Center will manage the center, to be located on its premises in Barcelona. Grifols will partner with other leading medical institutions to open expected future centers in the EU, U.S. and China, obtaining AMBAR® data from clinical practice and advancing further in the therapeutic management of the disease BARCELONA, Spain, May 19, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and well-being of people, today announced it's collaborating with the medical foundation Ace Alzheimer Center Barcelona to open the first AMBAR ® Center, where AMBAR ® procedure for Alzheimer's disease will be applied to obtain data from clinical practice.

Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona

BARCELONA, Spain, April 28, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and well-being of people, today announced it has signed an agreement with the government of Andorra through Andorra Development and Investment (ADI) to establish a global R+D+i hub to advance knowledge of the human immune system and investigate and develop new immune therapies. The planned facility, the Pyrenees Immunology Research Center (PYIRC), will focus on developing treatments for immune system disorders that can result in diseases including autoimmunity disorders, cancer and emerging infectious diseases.

Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics

A. O. Smith

Cboe Global Markets

ICON

Medical Properties Trust

According to the GuruFocus discounted cash flow calculator as of April 21, the following companies have a high margin of safety and have grown their margins over a 10-year period.

5 Profitable Stocks With a Margin of Safety

Grifols operates in the very attractive and lucrative plasma business.

Grifols: The Plasma-Supply Disruption Provides An Attractive Entry Point

BARCELONA, Spain, April 15, 2021   /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced that it will donate a minimum of 240 million international units (IU) of blood clotting factor medicines (Factor VIII and Factor IX) to the World Federation of Hemophilia (WFH) Humanitarian Aid Program over the next eight years, from 2022 to 2030. This contribution extends the company's commitment that began in 2014 and will bring its total humanitarian aid commitment to more than 440M IU of Factor VIII and Factor IX over 16 years.

Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030

BARCELONA, Spain, April 9, 2021 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 9, 2021.

Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021

BARCELONA, Spain, April 2, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial, also known as INSIGHT-013, sponsored and supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its primary endpoints with statistically significant results. The company will continue to move forward with its work on more than 20 research initiatives to find potential treatment options for different stages of COVID-19.

Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19

BARCELONA, Spain, March 22, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and leader in the development of innovative diagnostic solutions, today announced its first-ever installation in North America of the DG Reader Net semi-automated analyzer, used to facilitate pre-transfusion blood type compatibility testing. This platform, the newest addition to the company's scalable solutions for blood banks, is now running at ThedaCare Medical Center-Wild Rose in Wisconsin.

Grifols installs first-ever DG Reader Net analyzer in North America

BARCELONA, Spain, March 9, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the health and well-being of people worldwide, today announced the closing of its agreement...

Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins

Moving Average Crossover Alert: Grifols

Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.

Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug

BARCELONA, Spain, Jan. 18, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced it...

Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19

Good prospects for the global immunoglobulin business. Koru Medical's strategic plan is to reach $ 50M in sales by 2022, a gross margin of 70%, and organic and annual sales growth of + 20%.

Portfolio Manager Diary: Contrast The Information Obtained By The Company Management Before Investing

Let's see if Grifols (GRFS) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Consider Grifols (GRFS) Stock Now?

BARCELONA, Spain, Nov. 16, 2020 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with more than 100 years of history contributing to improve people's health and well-being, has...

News for Grifols, S.A. Stock (GRFS)